Immunohistochemical study of central neurocytoma, subependymoma, and subependymal giant cell astrocytoma

You, Heon; Kim, Young Im; Im, Soo Young; Suh‐Kim, Haeyoung; Paek, Sun Ha; Park, Sung Sup; Kim, Dong Gyu; Jung, Hee-Won

doi:10.1007/s11060-004-2354-2

Cited by 62 publications

(34 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…additionally, we also found all of our tumors to be entirely negative for CD34 (which is often positive in well-differentiated glio-neuronal tumors) and the tumors to be mostly negative for nF. This supports the results of You et al (24) who found all of their tumors (8/8) to be negative for nF, but is at odds with the findings of Sharma et al, (17) who found positive staining in 15/15 SEGa specimens. This may relate to the type of antibody used in the studies.…”

Section: Discussionsupporting

confidence: 77%

Evidence of ambiguous differentiation and mtor pathway dysregulation in subependymal giant cell astrocytoma

Barrows

Rutkowski

Gultekin

et al. 2012

TJPATH

View full text Add to dashboard Cite

Objective: The exact cell of origin of subependymal giant cell astrocytoma is debated but most currently consider the tumor in the astrocytic category. Mutations and subsequent biallelic inactivation of TSC1 encoding hamartin, or TSC2 encoding tuberin appear to be the underlying genetic aberrations. inactivation leads to loss of proteins that inhibit mammalian target of rapamycin (mTor) disrupting tightly regulated cell functions. Material and Method:We analyzed the expression of tuberin and hamartin along with an array of neuroepithelial markers in 9 subependymal giant cell astrocytomas. in addition, rPS6 and 4EBP1 regulatory proteins that are downstream in the mTor pathway were also evaluated.Results: While hamartin and tuberin expression levels were relatively decreased compared to control tissue, this was not of particular practical use to detect the mutated gene since low levels of positivity could be detected throughout the central nervous system. as expected, the levels of rPS6 and 4EBP1 were increased, further confirming the activation of the mTor pathway. GFaP was positive in 5 cases, while Synaptophysin positivity was found in all tumors. CD34 (a marker often observed in well differentiated glio-neuronal tumors), olig2 (a nuclear marker present in most gliomas), iDH1 and iDH2 were entirely negative in all tumor cells. Ki67 (MiB-1) showed a low proliferation rate ranging from 2% to 8%. Conclusion:Staining with neuroepithelial markers supports the suggestion of ambiguous differentiation. Subependymal giant cell astrocytomas do not appear to have the typical expression profiles of astrocytic tumors, under which they have been classified. Key Words: Subependymal giant cell astrocytoma, Hamartin, Tuberin, mTor complex, iDH1, iDH2, olig2 ÖZ Amaç: Subependimal dev hücreli astrositom hücre kökeni kesin olarak belirli olmamasına karşın astrositik tümörler arasında sınıflandırılan bir tümördür. Subependimal dev hücreli astrositomlarda tipik genetik anomali Hamartin'i kodlayan TSC1 veya Tuberin'i kodlayan TSC2 genlerindeki mutasyon ve diğer alelin inaktivasyonudur. Bu genlerin inaktivasyonu "rapamisin'in memelilerdeki hedefi" olarak bilinen mTor yolağı üzerinden hücrede sıkı biçimde kontrol edilen kritik işlevlerin bozulmasına neden olur. Gereç ve Yöntem:Bu çalışmada, 9 subependimal dev hücreli astrositom olgusunda Tuberin ve Hamartin yanısıra nöroepitelyal belirteçlerin düzeylerini immünhistokimyasal yöntemlerle inceledik. ayrıca mTor yolağında yer alan rPS6 and 4EBP1 proteinlerinin de düzeylerini araştırdık. Bulgular:Hamartin ve Tuberin antikorları normal dokuya oranla tümörlerde daha az boyansa da normale benzer düzeylerde bulunmaları genetik anomaliyi saptama açısından yarar sağlamadı. rPS6 ve 4EBP1 kuvvetli pozitifliğinin mTor yolağının aktivasyonunu gösterdiği görüşünü destekledi. İmmünhistokimyasal çalışmalarda GFaP sadece beş olguda kuvvetli pozitif olarak saptandı. Sinaptofizin bütün olgularda pozitif boyama gösterdi. Glionöronal tümörlerde tipik olarak görülen CD34 pozitifliği bu olgularda sapta...

show abstract

Section: Discussionsupporting

confidence: 77%

Evidence of ambiguous differentiation and mtor pathway dysregulation in subependymal giant cell astrocytoma

Barrows

Rutkowski

Gultekin

et al. 2012

TJPATH

View full text Add to dashboard Cite

show abstract

“…Moreover, nestin expression occurs in various human malignancies. As anticipated, it was commonly observed in neuroectodermal neuroepithelial tumours [6]. This protein was also recognized in other types of solid neoplasms e.g.…”

Section: Introductionsupporting

confidence: 67%

Clinical significance of nestin and its association with survival in neuroendocrine lung tumours

Bromińska¹,

Gabryel²,

Jarmołowska-Jurczyszyn³

et al. 2017

pjp

View full text Add to dashboard Cite

Nestin is considered to be a cancer stem cell marker. Nestin expression in neuroendocrine tumours might be useful to predict prognosis and facilitate treatment planning. 88 patients with neuroendocrine lung tumours operated in the Department of Thoracic Surgery from 2007 to 2015 were included into the study. Immunohistochemical staining for nestin was performed. Clinicopathological and survival data were retrospectively analyzed. Nestin expression was detected in 15 (17%) specimens. Multivariate analysis showed that lymph node metastases (p = 0.0001; hazard ratio (HR) = 3.93; confidence interval (CI) 95%: 1.96-7.87), nestin expression (p = 0.034; HR = 2.30; CI 95%: 1.06-4.99) and patient's age (p = 0.024; HR = 1.04; CI 95%: 1.00-1.09) were independent negative prognostic factors. Nestin expression was significantly higher in large cell neuroendocrine carcinoma when compared with carcinoids (p = 0.001). Collected data support the thesis that nestin can be regarded as a biomarker in patients with neuroendocrine lung tumours.

show abstract

“…It has been observed that nestin expression correlates with tumor malignancy and invasiveness [33,34]. In subependymal giant cell astrocytomas, pilocytic astrocytomas, and fibrillary astrocytomas, nestin is expressed weakly.…”

Section: Nestin In Neuroectodermal Neuroepithelial Tumorsmentioning

confidence: 99%

Nestin expression in human tumors and tumor cell lines.

Krupková¹,

Loja²,

Zambo³

et al. 2010

neo

View full text Add to dashboard Cite

The aim of this review is to summarize current knowledge on nestin expression in human tumors and corresponding tumor cell lines. Nestin belongs to class VI of the intermediate filaments and it is expressed primarily in mammalian nervous tissue during embryonic development. In adults, nestin occurs only in a small subset of cells and tissues. This protein has been observed in the subventricular zone of the adult mammalian brain, where neurogenesis is localized. Nestin expression has also been detected in various types of human solid tumors, as well as in the corresponding established cell lines. This article provides an up-to-date overview of tumors in which nestin has been found. Another aim of this review is to summarize recent findings on the intracellular localization of nestin in human tumor cells, especially with regard to the possible correlation between nestin expression and the malignant phenotype of transformed cells. Nestin expression in vascular endothelial cells during angiogenesis is also reviewed. Special attention is paid to the detection of nestin in cancer stem cells because this protein, together with the CD133 surface molecule, is considered to be a possible marker of cancer stem cells, especially in tumors of neuroectodermal origin.

show abstract

Immunohistochemical study of central neurocytoma, subependymoma, and subependymal giant cell astrocytoma

Cited by 62 publications

References 19 publications

Evidence of ambiguous differentiation and mtor pathway dysregulation in subependymal giant cell astrocytoma

Evidence of ambiguous differentiation and mtor pathway dysregulation in subependymal giant cell astrocytoma

Clinical significance of nestin and its association with survival in neuroendocrine lung tumours

Nestin expression in human tumors and tumor cell lines.

Contact Info

Product

Resources

About